Olaparib and bevacizumab in front-line maintenance of ovarian cancer: an over reliance in unpowered subgroup analysis of the PAOLA-1 trial?
J Gynecol Oncol
.
2020 Nov;31(6):e95.
doi: 10.3802/jgo.2020.31.e95.
Authors
Eduardo Paulino
1
,
Andreia Cristina de Melo
2
Affiliations
1
Brazilian National Cancer Institute and Grupo Oncoclínicas, Rio de Janeiro, Brazil. dudupaulino@globo.com.
2
Brazilian National Cancer Institute and Grupo Oncoclínicas, Rio de Janeiro, Brazil.
PMID:
33078600
PMCID:
PMC7593230
DOI:
10.3802/jgo.2020.31.e95
No abstract available
MeSH terms
Bevacizumab / therapeutic use*
Female
Humans
Ovarian Neoplasms* / drug therapy
Phthalazines / therapeutic use*
Piperazines / therapeutic use*
Substances
Phthalazines
Piperazines
Bevacizumab
olaparib